COSTI, Maria Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 38.032
EU - Europa 20.635
AS - Asia 19.194
SA - Sud America 2.730
AF - Africa 424
OC - Oceania 55
Continente sconosciuto - Info sul continente non disponibili 29
Totale 81.099
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 37.319
SG - Singapore 5.680
GB - Regno Unito 5.542
CN - Cina 5.501
IT - Italia 5.255
DE - Germania 2.618
VN - Vietnam 2.241
BR - Brasile 2.093
HK - Hong Kong 1.894
SE - Svezia 1.850
FR - Francia 1.101
RU - Federazione Russa 868
FI - Finlandia 789
BD - Bangladesh 767
KR - Corea 689
UA - Ucraina 678
IN - India 471
TR - Turchia 456
CA - Canada 413
PL - Polonia 407
ID - Indonesia 299
BG - Bulgaria 274
AR - Argentina 241
NL - Olanda 205
JP - Giappone 202
IQ - Iraq 179
MX - Messico 170
BE - Belgio 166
ES - Italia 145
IE - Irlanda 145
ZA - Sudafrica 132
LT - Lituania 113
PK - Pakistan 106
AE - Emirati Arabi Uniti 88
EC - Ecuador 84
CH - Svizzera 83
MY - Malesia 74
AT - Austria 71
CL - Cile 71
UZ - Uzbekistan 67
VE - Venezuela 64
IR - Iran 61
CO - Colombia 60
SA - Arabia Saudita 60
MA - Marocco 57
PH - Filippine 52
CZ - Repubblica Ceca 49
PY - Paraguay 49
JO - Giordania 45
AU - Australia 42
DZ - Algeria 40
KE - Kenya 40
EG - Egitto 37
PT - Portogallo 37
RO - Romania 35
TN - Tunisia 34
AZ - Azerbaigian 27
UY - Uruguay 27
ET - Etiopia 26
KZ - Kazakistan 26
NP - Nepal 26
PE - Perù 25
TW - Taiwan 24
JM - Giamaica 23
LU - Lussemburgo 22
EU - Europa 21
TH - Thailandia 20
DK - Danimarca 19
DO - Repubblica Dominicana 19
BY - Bielorussia 18
CR - Costa Rica 18
GR - Grecia 18
HU - Ungheria 18
AL - Albania 17
IL - Israele 17
BO - Bolivia 16
NO - Norvegia 15
BH - Bahrain 13
LB - Libano 13
OM - Oman 13
RS - Serbia 13
SN - Senegal 13
NZ - Nuova Zelanda 12
GT - Guatemala 11
HN - Honduras 11
KG - Kirghizistan 11
PS - Palestinian Territory 11
MD - Moldavia 10
NI - Nicaragua 10
QA - Qatar 10
BA - Bosnia-Erzegovina 9
LV - Lettonia 9
EE - Estonia 8
GE - Georgia 8
NG - Nigeria 8
PA - Panama 8
SK - Slovacchia (Repubblica Slovacca) 8
TT - Trinidad e Tobago 7
AM - Armenia 6
GA - Gabon 6
Totale 80.979
Salva come PNG Salva come JPEG
Città #
Southend 3.786
Ashburn 3.709
Santa Clara 3.489
Singapore 3.423
Fairfield 2.984
Houston 2.382
Woodbridge 2.116
Chandler 2.083
Hong Kong 1.849
Hefei 1.774
San Jose 1.561
Frankfurt am Main 1.258
Ann Arbor 1.253
Jacksonville 1.235
Seattle 1.173
Cambridge 1.141
Dearborn 1.137
Wilmington 1.069
Nyköping 1.004
Beijing 860
Modena 836
London 790
Ho Chi Minh City 705
Council Bluffs 663
Los Angeles 658
Seoul 642
New York 607
Hanoi 513
Helsinki 510
The Dalles 432
Chicago 424
Milan 339
Princeton 287
San Diego 277
Sofia 268
Shanghai 264
Lauterbourg 258
Moscow 258
Kraków 255
Munich 234
Eugene 229
Buffalo 211
Jakarta 205
Bologna 199
Izmir 196
São Paulo 196
Boardman 182
Orem 176
Fremont 174
Redwood City 156
Rome 142
Tokyo 139
Dallas 137
Salt Lake City 136
Dublin 132
Des Moines 129
Brussels 128
Bremen 123
Warsaw 121
Da Nang 116
Parma 100
Porto Alegre 96
Denver 92
Atlanta 90
Ottawa 90
Chennai 88
Guangzhou 88
Phoenix 83
Reggio Emilia 83
Brooklyn 79
Toronto 79
Haiphong 77
Columbus 76
Tampa 76
Amsterdam 74
Elk Grove Village 73
Montreal 70
Falls Church 67
Stockholm 66
Turku 66
Naples 65
Kent 63
Baghdad 62
Rio de Janeiro 62
Grafing 58
Johannesburg 58
Mexico City 58
Manchester 57
Tashkent 57
Turin 56
Belo Horizonte 55
Verona 54
Dong Ket 52
Paris 51
Poplar 51
Dhaka 49
Nanjing 49
Brasília 46
Norwalk 45
San Francisco 45
Totale 54.439
Salva come PNG Salva come JPEG
Nome #
Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase 1.218
STRUTTURA DEL CRISTALLO DEL COMPLESSO DI TIMIDILATO SINTETASI (TS) CON UN LIGANDO 828
TYDOCK PHARMA s.r.l. Spin Off dell'Università di Modena e Reggio Emilia che ha come fine l'attività di ricerca e sviluppo nel settore delle biotech farmaceutiche. 669
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase 486
Spermidine/spermine N1-acetyltranferasemodulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistanthuman ovarian cancer cell lines 472
Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth 461
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics 456
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells 454
An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases 451
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. 443
2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes 436
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 435
Metodo per la funzionalizzazione sito specifica di molecole proteiche 430
Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase 429
Constrained dansyl derivatives reveal bacterial specificity of highly conserved Thymidylate Synthases A 427
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase 426
New thymidylate synthase inhibitors induce apoptosis in melanoma cell lines 423
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections 418
USO DI INIBITORI DELLA PTERIDINA REDUTTASI PER LA PREVENZIONE E/O IL TRATTAMENTO DI INFEZIONI PARASSITARIE 414
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections 409
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth 409
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform 408
Internalization and stability of a thymidylate synthase peptide inhibitor in ovarian cancer cells 401
Translational repression of thymidylate synthase by targeting its mRNA 398
Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery 397
Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology 396
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines 394
Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones? 394
Antibacterial agent discovery using thymidylate synthase biolibrary screening 393
Repurposing of drugs targeting yap-tead functions 392
A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics 391
Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-beta-lactamases 386
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth 385
Biochemistry: Anchors away 385
Structure-based studies on species-specific inhibition of thymidylate synthase 376
2′-Deoxyuridine 5′-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives 371
pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells 371
Alanine Mutants of the Interface Residues of Human Thymidylate Synthase Decode Key Features of the Binding Mode of Allosteric Anticancer Peptides 369
Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides 368
Proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer 363
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance 362
Decoding the structural basis for carbapenem hydrolysis by class A β- lactamases: fishing for a pharmacophore 361
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs 359
Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins 358
Allosteric Inhibition of human Thymidylate Synthase. 357
Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine 356
Multiligand approach to the identification of resistant strains overexpressing beta-lactamase 355
Structure-Based Selectivity Optimization of Piperidine–Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors 352
Thymidylate synthase structure, function and implication in drug discovery 351
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 351
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells 348
Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer 347
Crystal Structure of human thymidylate synthase bound to a peptide inhibitor 343
Maxwell A: F1000Prime Recommendation of Evaluation [Neres J et al., ACS Chem Biol 2014]. In F1000Prime, 09 Jan 2015; DOI: 10.3410/f.725248139.793502885. F1000Prime.com/725248139#eval793502885 343
A proteomic approach to investigate the mechanism of action of anticancer peptides 342
NUOVE MOLECOLE, PER USO COME AGENTI ANTITUMORALI 342
Proteomic Approach to the Detection of the Mechanism of Action of Anticancer Peptides 342
Current and Future Chemotherapy for Chagas Disease 342
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity 341
Crystal Structure of histidine-tagged human thymidylate synthase 340
Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding 337
Development of flavonoids derivatives as leads against Leishmaniasis and Trypanosomiasis-invited lecture 336
Aprepitant as anticancer drug 334
Theoretical study of electronic spectra and photophysics of uracil derivatives. 334
Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections 331
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development 329
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations 328
ANTICANCER DRUGS 328
IN SILICO/IN VITRO APPROACHES FOR THE IDENTIFICATION OF NEW CARBAPENEMASE INHIBITORS 328
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery 325
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells 322
X-ray-crystallography deciphers the activity of broad spectrum boronic acid β-Lactamases inhibitors 322
“A step further in the discovery of phthalein derivatives as Thymidylate Synthase inhibitors” 321
Hotspots in an obligate homodimeric anticancer target. structural and functional effects of interfacial mutations in human thymidylate synthase 321
Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors 320
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 320
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds 319
PTEROATE-PEPTIDE BIOCONJUGATE TARGETING THE FOLATE RECEPTOR IN HUMAN OVARIAN CANCER CELL LINES: TRANSPORT AND MECHANISM OF ACTION. 319
The 1,10-phenanthroline ligand enhances the antiproliferative activity of dna-intercalating thiourea-pd(Ii) and-pt(ii) complexes against cisplatin-sensitive and-resistant human ovarian cancer cell lines 317
Biochemical effects of riluzole on Leishmania parasites 315
Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents 314
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase 314
Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors 312
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting 312
Homodimeric Enzymes as Drug Targets 311
Alternative strategies in medicinal chemistry to face drug resistance in anticancer therapy. 311
CYCLIZATION REACTIONS OF 1,3-DIBROMOPROPAN-2-OL, 2,3-DIBROMOPROPAN-1-OL AND 1-BROMOMETHYLOXIRANE WITH 6-AMINO-2,3-DIHYDRO-2-THIOXO-4(1H)-PYRIMIDINONE 310
1H-NMR conformational studies of some phtalein derivatives acting as thymidylate synthase inhibitors 309
Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth 309
Optimizing Cell Permeation of an Antibiotic Resistance Inhibitor for Improved Efficacy 309
The Inhibition of Extended Spectrum beta-Lactamases: Hits and Leads 307
Thymidylate synthase inhibition: A structure-based rationale for drug design 306
MITO-group Multicenter italian trials in ovarian cancer and gynecological malignancies Borad of directors-translational research group 304
Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer-US8916679 “B2 - Granted patent as second publication”. 302
Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the Thymidylate synthase reaction 299
Designing selective Cys-ligands to unpair the binding of the Human Transcription Enhancer Associated Domain 4 (hTEAD-4) with its modulators to halt cancer cell growth 298
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity 296
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent 296
Permeation through the cell membrane of a boron-based β-lactamase inhibitor. 295
Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case 295
Totale 37.539
Salva come PNG Salva come JPEG
Categoria #
all - tutte 292.191
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 292.191
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021398 0 0 0 0 0 0 0 0 0 0 0 398
2021/20225.516 246 534 330 303 243 554 249 355 621 393 1.054 634
2022/20236.264 753 755 420 606 640 882 184 600 740 101 304 279
2023/20245.608 193 275 323 408 1.981 485 280 485 137 133 368 540
2024/202514.094 598 193 422 930 2.626 1.846 973 796 1.419 644 1.690 1.957
2025/202625.615 1.678 1.167 2.018 2.904 3.763 1.797 3.219 1.293 2.403 2.454 1.675 1.244
Totale 81.807